Genomictree Inc. (228760) — Strategic Asset Allocation Index
Genomictree Inc. (228760) has a Strategic Asset Allocation Index of 14.9% as of March 2025. Strategic assets (PP&E of ₩18.11 Billion plus long-term investments of ₩-) total ₩18.11 Billion, measured against net assets of ₩121.20 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Genomictree Inc.'s balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Genomictree Inc. Strategic Asset Allocation Index (2020–2024)
This chart shows how Genomictree Inc.'s Strategic Asset Allocation Index has evolved across 4 annual periods from 2020 to 2024. As of March 2025, the index stands at 14.9%, representing strategic assets of ₩18.11 Billion against net assets of ₩121.20 Billion KRW. For live market cap and overall valuation, see 228760 company net worth.
Annual Strategic Asset Allocation Index for Genomictree Inc. (2020–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Genomictree Inc. from 2020 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 228760 net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (KRW) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 14.8% | ₩18.39 Billion | ₩18.39 Billion | ₩- | ₩124.32 Billion | ▲ +0.8 pp |
| 2023 | 14.0% | ₩17.46 Billion | ₩17.46 Billion | ₩- | ₩125.03 Billion | ▼ -2.7 pp |
| 2022 | 16.7% | ₩17.87 Billion | ₩17.87 Billion | ₩- | ₩107.05 Billion | ▲ +5.5 pp |
| 2020 | 11.2% | ₩10.63 Billion | ₩10.63 Billion | ₩- | ₩95.26 Billion | — |